跳至主要内容
临床试验/NCT04184258
NCT04184258已完成1 期

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2019年7月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
7
试验地点
1
主要终点
Efficacy evaluation

研究概览

简要总结

Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •SLE diagnosis (4 of 11 criteria by ACR);
  • •positive dsDNA;
  • •SELENA-SLEDAI index ≥6;
  • •active lupus nephritis;
  • •patient can read, understand and follow the procedures.

排除标准

  • •need for dialysis;
  • •planned renal transplantation;
  • •any medical condition which can be associated with the high risk for the patient;
  • •pregnancy/lactation;
  • •chronic infections, including hepatitis B/C, tuberculosis, HIV;
  • •any malignant tumor in the last 5 years.

研究组 & 干预措施

SLE patients MSC treatment

Experimental

Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols

干预措施: Standard treatment according to the Clinical protocols (Other)

SLE patients standard treatment

Active Comparator

Patients with SLE, who receive standard treatment according to the Clinical protocols

干预措施: Standard treatment according to the Clinical protocols (Other)

SLE patients MSC treatment

Experimental

Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols

干预措施: Pooled mesenchymal stem cell (Biological)

结局指标

主要结局

Efficacy evaluation

时间窗: 6 month

Efficacy evaluation (SELENA-SLEDAI)

次要结局

  • Safety eveluation(1 month)

研究者

研究点 (1)

Loading locations...

相似试验